Comparative Pharmacology
Head-to-head clinical analysis: KLEBCIL versus PEN VEE K.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KLEBCIL versus PEN VEE K.
KLEBCIL vs PEN-VEE K
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Klebcillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Penicillin V binds to penicillin-binding proteins (PBPs) located on the bacterial cell wall, inhibiting the final transpeptidation step of peptidoglycan synthesis, leading to cell lysis.
KLEBCIL (ceftazidime-avibactam) 2.5 g (ceftazidime 2 g + avibactam 0.5 g) IV every 8 hours infused over 2 hours.
250-500 mg orally every 6-8 hours for mild to moderate infections; up to 2 g/day for severe infections.
None Documented
None Documented
2-3 hours (prolonged to 30-60 hours in severe renal impairment; adjust dosing)
Terminal elimination half-life: 30-60 minutes in adults with normal renal function, prolonged to 3-10 hours in severe renal impairment.
Primarily renal (70-80% unchanged); minor biliary/fecal (15-20%)
Renal excretion of unchanged drug via glomerular filtration and tubular secretion accounts for 60-90% of elimination; biliary/fecal elimination is minimal (<10%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic